Navigation Links
Melanoma drug revs immune cells but cancer cells ignore it
Date:9/2/2007

COLUMBUS , Ohio A new study shows that an important drug used in the treatment of malignant melanoma has little effect on the melanoma cells themselves. Instead, it activates immune-system cells to fight the disease.

The drug, called interferon alpha (IFNa), is used to clean up microscopic tumor cells that may remain in the body following surgery for the disease. It is the only drug approved for this purpose.

Researchers say that these findings underscore the need to develop ways to make melanoma cells more vulnerable to the drug, or to overcome the block within the cells that prevents them from responding to it.

The study showed that melanoma cells taken directly from patients, as well as those grown in the laboratory, respond poorly to IFNa, even when the drug is given at very high doses, while immune cells respond well to the same substance.

The study, led by researchers with the Ohio State University Comprehensive Cancer Center, is published in the journal Clinical Cancer Research.

IFNa is effective in only 10 to 20 percent of patients, but it's the best therapy available for these patients, and no therapies on the horizon have been proven any more effective, says principal investigator William E. Carson, III, professor of surgery and a melanoma specialist at Ohio State's James Cancer Hospital and Solove Research Institute.

It is critical that we understand exactly how this drug works and learn how to improve its effectiveness.

IFNa is an immune-system hormone made by the body to help other immune cells recognize and destroy developing tumors. As a drug, the substance is used to treat melanoma and other cancers.

Formerly, it was thought that IFNa acted directly on melanoma-tumor cells to stop their growth. But earlier research by Carson's laboratory and others suggested that the drug has a greater effect on the immune system.

The present study confirms that earlier work, says first author Gregory B. Lesinski, a research assistant professor in the department of molecular virology, immunology and medical genetics. The new findings are significant because they confirm that the immune system, and not the tumor cell, is the primary target of IFNa.

We show for the first time that even normal melanocytes are inherently less responsive to IFNa compared to immune cells. Melanocytes are the normal cells that, when cancerous, cause melanoma.

Some unknown factor in melanoma cells seems to turn down their response to IFNa, Lesinski explains. We are now trying to understand what that factor might be.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
Source:Eurekalert

Related medicine news :

1. UV Radiation induces Melanoma
2. Reduction in melanoma death rate
3. Latest device for identifying Melanomas
4. Specialist surgeon not imperative in melanoma
5. Tumour marker for melanoma found
6. Melanoma caused by low DNA repair capacity
7. Hope for First New Melanoma Treatment in Decades
8. Turmeric Found To Slow Down Melanoma Growth
9. Gene in Melanomas
10. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
11. Skin Cancer History Puts Post-menopausal White Women At Risk For Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 21, 2017 , ... ... its new medical office in Petaluma, located at 167 Lynch Creek Way. The ... to SRO sports medicine and rehabilitation services and on-site x-ray services. ...
(Date:1/20/2017)... ... , ... A new partnership between Goodwill® and Roadie, Inc. aims to make ... clothes to couches to dressers and bicycles. Roadie — the national on-the-way delivery network ... donation center through February 28th. , “January is an exciting time when resolutions ...
(Date:1/20/2017)... ... , ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality ... January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures ... its products to all clients at reasonable prices. At the ECRM trade show, it ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... ... , ... “The Angel”: a heartwarming and earnest tale of faith and ... children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional ... writer. , When asked of her new book, Marjorie says, “‘The Angel’ was written ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
Breaking Medicine Technology: